ArticleOncotarget2017

Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial.

Luca Moscetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.